Pancreatic Cancer Research

ResearcherTongji UniversityActive in the last 2 years

Keping Xie

ORCID-verified (high confidence, 0.95), identity_conf@1As of 6 November 2026

Matched on ORCID iD 0000-0001-7887-9586; OpenAlex author ID A5059889471, A5064840682; NIH RePORTER profile ID 2620552. Sources: OpenAlex.

Their work

Papers
50 (first author 4, last author 35)
Trials
0
Grants
6
Labs led
2
Collaborators
96
Papers, trials and grants by year

2011: 1 paper · 2012: 4 papers, 1 grant · 2013: 5 papers · 2014: 7 papers, 2 grants · 2015: 4 papers · 2016: 2 papers · 2017: 4 papers, 1 grant · 2018: none · 2019: 1 paper · 2020: 3 papers · 2021: 2 papers, 2 grants · 2022: 2 papers · 2023: 1 paper · 2024: 3 papers · 2025: 7 papers · 2026: 4 papers

Papers 50

  1. Oncogenic Peptide Encoded by Noncoding RNA of FOXM1 Promotes Pancreatic Cancer Malignancy Through PI3K/AKT Signaling. Last author DOI 10.1002/mc.70051↗
  2. Up-regulated IL-36 expression promotes a pro-tumorigenic phenotype in pancreatic ductal adenocarcinoma. Last author DOI 10.1016/j.gendis.2025.101973↗
  3. Unraveling the role of PPFIA1 in cancer: a comprehensive multi-omics analysis and functional validation from pan-cancer to pancreatic cancer. Last author DOI 10.3389/fonc.2026.1723550↗
  4. OSBPL3-driven sterol metabolic reprogramming promotes oncogenic signaling and therapeutic resistance in pancreatic cancer. Last author DOI 10.7150/thno.113637↗
  5. FOXM1-Cx31 Axis Drives Pancreatic Cancer Stem Cell-Like Properties and Chemoresistance. Last author DOI 10.1002/mc.23870↗
  6. Cingulin is an RNA-binding protein promoting pancreatic cancer through enhancing importin 7-mediated phospho-ERK nuclear translocation. Last author DOI 10.1016/j.celrep.2025.115925↗
  7. GATA6 in pancreatic cancer initiation and progression. Last author DOI 10.1016/j.gendis.2024.101353↗
  8. OSBPL3 modulates the immunosuppressive microenvironment and predicts therapeutic outcomes in pancreatic cancer. Co-author DOI 10.1186/s13062-025-00596-0↗
  9. Machine learning-driven prognostic model based on sphingolipid-related gene signature in pancreatic cancer: development and validation. Co-author DOI 10.21037/tcr-24-1893↗
  10. Innate immune cell barrier-related genes inform precision prognosis in pancreatic cancer. Last author DOI 10.3389/fimmu.2025.1559373↗
  11. FOXM1-Driven CKS1B Upregulation Promotes Pancreatic Cancer Progression and Therapeutic Resistance. Co-author DOI 10.7150/ijbs.105289↗
  12. Down-regulation of microRNA-23a promotes pancreatic ductal adenocarcinoma initiation and progression by up-regulation of FOXM1 expression. Co-author DOI 10.1016/j.gendis.2023.101203↗
  13. Unveiling the role of interleukin-6 in pancreatic cancer occurrence and progression. Last author DOI 10.3389/fendo.2024.1408312↗
  14. Pancreatic stellate cells and the interleukin family: Linking fibrosis and immunity to pancreatic ductal adenocarcinoma (Review). Last author DOI 10.3892/mmr.2024.13283↗
  15. Nuclear GRP78 Promotes Metabolic Reprogramming and Therapeutic Resistance in Pancreatic Ductal Adenocarcinoma. Last author DOI 10.1158/1078-0432.ccr-23-1143↗
  16. Molecular signaling in pancreatic ductal metaplasia: emerging biomarkers for detection and intervention of early pancreatic cancer. Last author DOI 10.1007/s13402-022-00664-x↗
  17. RASAL2 mediated the enhancement of YAP1/TIAM1 signaling promotes malignant phenotypes of pancreatic ductal adenocarcinoma. Co-author DOI 10.7150/ijbs.72204↗
  18. Therapeutic resistance of pancreatic cancer: Roadmap to its reversal. Last author DOI 10.1016/j.bbcan.2020.188461↗
  19. Coupled liquid biopsy and bioinformatics for pancreatic cancer early detection and precision prognostication. Last author DOI 10.1186/s12943-021-01309-7↗
  20. Protein arginine methylation promotes therapeutic resistance in human pancreatic cancer. Last author DOI 10.1016/j.cytogfr.2020.07.011↗
  21. A novel KDM5A/MPC-1 signaling pathway promotes pancreatic cancer progression via redirecting mitochondrial pyruvate metabolism. Last author DOI 10.1038/s41388-019-1051-8↗
  22. Methylation of HSP70 Orchestrates Its Binding to and Stabilization of BCL2 mRNA and Renders Pancreatic Cancer Cells Resistant to Therapeutics. Last author DOI 10.1158/0008-5472.can-19-1738↗
  23. LIMS1 Promotes Pancreatic Cancer Cell Survival under Oxygen-Glucose Deprivation Conditions by Enhancing HIF1A Protein Translation. Co-author DOI 10.1158/1078-0432.ccr-18-3533↗
  24. ESE3 Inhibits Pancreatic Cancer Metastasis by Upregulating E-Cadherin. Co-author DOI 10.1158/0008-5472.can-16-2170↗
  25. STK33 Promotes Growth and Progression of Pancreatic Cancer as a Critical Downstream Mediator of HIF1α. Last author DOI 10.1158/0008-5472.can-17-0067↗
  26. The Novel KLF4/MSI2 Signaling Pathway Regulates Growth and Metastasis of Pancreatic Cancer. Last author DOI 10.1158/1078-0432.ccr-16-1064↗
  27. DNA-Methyltransferase 1 Induces Dedifferentiation of Pancreatic Cancer Cells through Silencing of Krüppel-Like Factor 4 Expression. Co-author DOI 10.1158/1078-0432.ccr-17-0387↗
  28. KLF4-Mediated Suppression of CD44 Signaling Negatively Impacts Pancreatic Cancer Stemness and Metastasis. Last author DOI 10.1158/0008-5472.can-15-1691↗
  29. Molecular Biomarkers of Pancreatic Intraepithelial Neoplasia and Their Implications in Early Diagnosis and Therapeutic Intervention of Pancreatic Cancer. First author DOI 10.7150/ijbs.14995↗
  30. Pancreatic cancer stromal biology and therapy. First author DOI 10.1016/j.gendis.2015.01.002↗
  31. Activation of vitamin D receptor signaling downregulates the expression of nuclear FOXM1 protein and suppresses pancreatic cancer cell stemness. Last author DOI 10.1158/1078-0432.ccr-14-2437↗
  32. Hippo transducer TAZ promotes epithelial mesenchymal transition and supports pancreatic cancer progression. Co-author DOI 10.18632/oncotarget.5772↗
  33. Vitamin D receptor signaling and pancreatic cancer cell EMT. Co-author DOI 10.2174/1381612821666141211151138↗
  34. FOXM1 and its oncogenic signaling in pancreatic cancer pathogenesis. Last author DOI 10.1016/j.bbcan.2014.01.002↗
  35. Down-regulation of microRNA-494 via loss of SMAD4 increases FOXM1 and β-catenin signaling in pancreatic ductal adenocarcinoma cells. Last author DOI 10.1053/j.gastro.2014.04.048↗
  36. FOXM1c promotes pancreatic cancer epithelial-to-mesenchymal transition and metastasis via upregulation of expression of the urokinase plasminogen activator sys… Last author DOI 10.1158/1078-0432.ccr-13-2311↗
  37. FOXM1 promotes the warburg effect and pancreatic cancer progression via transactivation of LDHA expression. Last author DOI 10.1158/1078-0432.ccr-13-2407↗
  38. Sonic hedgehog paracrine signaling activates stromal cells to promote perineural invasion in pancreatic cancer. Last author DOI 10.1158/1078-0432.ccr-13-3426↗
  39. A novel KLF4/LDHA signaling pathway regulates aerobic glycolysis in and progression of pancreatic cancer. Last author DOI 10.1158/1078-0432.ccr-14-0186↗
  40. Targeting miRNAs for pancreatic cancer therapy. Last author DOI 10.2174/1381612820666140128210443↗
  41. Analysis of the potential for pancreatic cancer metastasis in vitro and in vivo. First author DOI 10.1007/978-1-62703-287-2_17↗
  42. Dysregulated expression of FOXM1 isoforms drives progression of pancreatic cancer. Last author DOI 10.1158/0008-5472.can-12-3859↗
  43. Lamin B1 is a novel therapeutic target of betulinic acid in pancreatic cancer. Last author DOI 10.1158/1078-0432.ccr-12-3630↗
  44. Interaction of the sympathetic nerve with pancreatic cancer cells promotes perineural invasion through the activation of STAT3 signaling. Last author DOI 10.1158/1535-7163.mct-12-0809↗
  45. Altered sphingolipid metabolism in patients with metastatic pancreatic cancer. Co-author DOI 10.3390/biom3030435↗
  46. Crosstalk of Sp1 and Stat3 signaling in pancreatic cancer pathogenesis. First author DOI 10.1016/j.cytogfr.2012.01.003↗
  47. Targeted destruction of the orchestration of the pancreatic stroma and tumor cells in pancreatic cancer cases: molecular basis for therapeutic implications. Last author DOI 10.1016/j.cytogfr.2012.06.006↗
  48. A novel FoxM1-caveolin signaling pathway promotes pancreatic cancer invasion and metastasis. Last author DOI 10.1158/0008-5472.can-11-3102↗
  49. Role of Wnt/β-catenin signaling in drug resistance of pancreatic cancer. Last author DOI 10.2174/13816128112092464↗
  50. Combining betulinic acid and mithramycin a effectively suppresses pancreatic cancer by inhibiting proliferation, invasion, and angiogenesis. Last author DOI 10.1158/0008-5472.can-10-2016↗

Grants 6

  1. Clinical Significance of Pancreatic Cancer Differentiation and Dedifferentiation R01CA195651↗
  2. Integrated Signaling in Pancreatic Cancer Progression R01CA198090↗
  3. Molecular Mediators of Pancreatic Cancer Invasion and Progression R01CA172233↗
  4. Genetic Approaches to Pancreatic Cancer Progression R01CA148954↗
  5. Functional Validation of Pancreatic Cancer Progression Biomarker R01CA152309↗
  6. KLF4 Genetic and Epigenetic Changes in Human Pancreatic Cancer R01CA129956↗

Closest collaborators

The 25 strongest of 96 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Xiaojia Li · 8 shared papers, 2022–2026 · strength 2.20
  2. Dacheng Xie · 12 shared papers, 2014–2025 · strength 1.09
  3. Qihui Sun · 4 shared papers, 2023–2026 · strength 1.01
  4. Jianhong An · 3 shared papers, 2024–2026 · strength 0.87
  5. Robert S. Bresalier · 2 shared grants, 2017–2021 · strength 0.85
  6. Fang Wei · 3 shared papers, 2023–2025 · strength 0.67
  7. Jiujie Cui · 11 shared papers, 2012–2020 · strength 0.57
  8. Huamin Wang · 1 shared grant, 2021 · strength 0.56
  9. Daoyan Wei · 10 shared papers, 2011–2020 · strength 0.53
  10. Xinyan Huang · 2 shared papers, 2025–2026 · strength 0.53
  11. Xiangyu Kong · 8 shared papers, 2011–2023 · strength 0.47
  12. Yuling Su · 2 shared papers, 2025 · strength 0.45
  13. Yong Gao · 8 shared papers, 2011–2020 · strength 0.44
  14. Tiansuo Zhao · 4 shared papers, 2017–2023 · strength 0.42
  15. Shu Li · 1 shared paper, 2026 · strength 0.39
  16. Muyuan Ma · 1 shared paper, 2025 · strength 0.37
  17. Fanyang Kong · 3 shared papers, 2017–2023 · strength 0.35
  18. Qiang Yi Luo · 1 shared paper, 2025 · strength 0.33
  19. Chen Huang · 6 shared papers, 2012–2014 · strength 0.33
  20. Jihui Hao · 3 shared papers, 2017–2023 · strength 0.31
  21. Qi Zou · 1 shared paper, 2025 · strength 0.28
  22. Meihui Song · 1 shared paper, 2024 · strength 0.28
  23. Qingyong Ma · 4 shared papers, 2013–2022 · strength 0.28
  24. Victoria K. Xie · 2 shared papers, 2017–2020 · strength 0.25
  25. Jia Liu · 1 shared paper, 2025 · strength 0.25

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.